XML 73 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
Inventory
9 Months Ended
Sep. 30, 2014
Inventory Disclosure [Abstract]  
Inventory
Inventory
The components of inventory are summarized as follows:
(In millions)
As of
September 30,
2014
 
As of
December 31,
2013
Raw materials
$
133.8

 
$
115.0

Work in process
478.6

 
435.4

Finished goods
140.7

 
108.6

Total inventory
$
753.1

 
$
659.0


As of September 30, 2014, our inventory includes $5.6 million associated with our ZINBRYTA (Daclizumab High Yield Process) program, which has been capitalized in advance of regulatory approval. As of December 31, 2013, our inventory included $93.7 million associated with our ALPROLIX, ELOCTATE and PLEGRIDY programs, which were capitalized in advance of regulatory approval. ALPROLIX, ELOCTATE and PLEGRIDY were subsequently approved during the nine months ended September 30, 2014.